Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

XMMO

Invesco S&P MidCap Momentum ETF (XMMO)

Rating:71Outperform
Price Target:$152.00â–²(12.12% Upside)

XMMO, the Invesco S&P MidCap Momentum ETF, earns a solid overall rating thanks to several strong core holdings with healthy growth and positive outlooks, such as TechnipFMC and ATI, which show robust financial performance and supportive technical trends. United Therapeutics and TD SYNNEX also add strength through solid revenues and strategic initiatives, though names like Roivant Sciences and Jazz Pharmaceuticals, with weaker financial performance and valuation concerns, slightly weigh on the fund. The main risk factor is its focus on mid-cap momentum stocks, which can lead to higher volatility and sensitivity to shifts in market sentiment.

Positive Factors
Strong Top HoldingsMost of the fund’s largest positions have shown strong year-to-date gains, helping support overall performance despite recent weakness.
Broad Sector MixThe ETF spreads its investments across many sectors like technology, industrials, health care, and energy, which can help reduce the impact of a downturn in any single industry.
Meaningful Asset BaseThe fund manages a large pool of assets, which can improve trading liquidity and make it easier for investors to buy and sell shares.
Negative Factors
Recent Performance WeaknessThe ETF has shown weak returns over the past month, three months, and year to date, indicating momentum has recently turned negative.
High U.S. ConcentrationAlmost all of the fund’s holdings are in U.S. companies, offering very limited geographic diversification outside the United States.
Moderate Expense RatioThe fund’s fees are not extremely high but are also not among the lowest, which slightly reduces the net return investors keep over time.

XMMO vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%SPY+14.55%XMMO+3.16%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
6.39B
Region
North America
Expense Ratio
0.34%
Beta
1.02
Issuer
Invesco
Inception Date
Mar 03, 2005
Dividend Yield
0.73%
Asset Class
Equity
Index Tracked
S&P MidCap 400 Momentum Index (USD)

XMMO Summary

XMMO is the Invesco S&P MidCap Momentum ETF, which follows the S&P MidCap 400 Momentum Index. It focuses on medium‑sized U.S. companies that have been rising in price, aiming to capture ongoing growth trends. The fund spreads money across many sectors, including technology, industrials, health care, and energy. Well-known names in the ETF include United Therapeutics and TD SYNNEX Corporation. Someone might invest in XMMO to seek growth while diversifying beyond large, well-known stocks. A key risk is that momentum stocks can fall quickly, and the ETF’s value can go up and down with the overall stock market.

How much will it cost me?

This ETF has an expense ratio of 0.34%, which means you’ll pay about $3.40 per year for every $1,000 you invest. That cost is slightly higher than the cheapest index ETFs because it tracks a more specialized momentum strategy rather than a plain-vanilla broad market index.

What would affect this ETF?

This ETF is focused on U.S. mid-sized companies with strong recent stock performance, especially in technology, industrials, health care, and energy, so it could benefit if the U.S. economy stays healthy, business investment grows, and market leaders in these sectors keep doing well. On the other hand, it could be hurt by rising interest rates, an economic slowdown that hits mid-sized companies harder than large ones, or sector-specific setbacks in areas like health care regulation or energy prices that weigh on its top holdings.

XMMO Top 10 Holdings

XMMO is leaning hard into U.S. mid-cap momentum, with a clear tilt toward industrials, energy, and health care rather than the usual Big Tech suspects. TechnipFMC and HF Sinclair have been rising steadily, giving the fund a strong energy engine, while United Therapeutics and Roivant add a healthy dose of biotech momentum. On the flip side, names like MKS Instruments and Jazz Pharmaceuticals have been lagging lately, acting as a bit of a brake. Overall, it’s a domestically focused, sector-diversified bet on mid-cap companies that are currently in motion.

XMMO top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
ROIVROIVRoivant Sciences4.22%$267.19M$28.64B92.27%58Neutral
ATIATIATI4.19%$265.13M$24.87B85.77%78Outperform
FTIFTITechnipFMC4.25%$268.84M$25.76B53.52%80Outperform
MKSIMKSIMKS2.61%$165.51M$14.58B49.64%75Outperform
JAZZJAZZJazz Pharmaceuticals2.61%$165.37M$15.50B70.45%64Neutral
UTHRUTHRUnited Therapeutics2.66%$168.53M$25.18B27.88%79Outperform
DINODINOHF Sinclair Corporation2.57%$162.98M$17.51B89.12%68Neutral
SNXSNXTD SYNNEX Corporation2.52%$159.73M$18.95B57.90%73Outperform
BTSGBTSGBrightSpring Health Services, Inc.2.39%$151.20M$14.17B124.28%67Neutral
LSCCLSCCLattice Semiconductor2.12%$134.47M$15.98B73.97%71Outperform

XMMO Technical Analysis

Technical Analysis SentimentNegative
Last Price135.57

Price Trends

50DMA143.40Negative
100DMA151.38Negative
200DMA153.21Negative

Market Momentum

MACD-2.57Negative
RSI45.02Neutral
STOCH84.05Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XMMO, the sentiment is Negative. The current price of 135.57 is below the 20-day moving average (MA) of 136.31, below the 50-day MA of 143.40, and below the 200-day MA of 153.21, indicating a bearish trend. The MACD of -2.57 indicates Negative momentum. The RSI at 45.02 is Neutral, neither overbought nor oversold. The STOCH value of 84.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XMMO.

XMMO Peer Comparison

Comparison Results

XMMO against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
XMMOXMMO$135.57$152.00(12.12% Upside)$6.39B0.34%71Outperform
FMDEFMDE$41.91$49.30(17.64% Upside)$8.88B0.23%69Neutral
JHMMJHMM$74.06$88.26(19.17% Upside)$6.18B0.41%70Neutral
XMHQXMHQ$120.09$138.38(15.23% Upside)$5.79B0.25%74Outperform
DONDON$58.29$64.87(11.29% Upside)$4.04B0.38%70Neutral
IVOOIVOO$124.94$155.49(24.45% Upside)$3.86B0.07%70Outperform

Performance Comparison

0%10%20%30%XMMOFMDEJHMMXMHQDONIVOODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
XMMO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
XMMOInvesco S&P MidCap Momentum ETF135.574.043.07%
FMDEFidelity Enhanced Mid Cap ETF41.917.3521.28%
JHMMJohn Hancock Multifactor Mid Cap ETF74.0611.7918.93%
XMHQInvesco S&P MidCap Quality ETF120.0921.4521.74%
DONWisdomTree U.S. MidCap Dividend Fund58.299.5219.53%
IVOOVanguard S&P Mid-Cap 400 ETF124.9419.7118.73%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.